Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
Helene Häberle,Harry Magunia,Peter Lang,Henning Gloeckner,Andreas Körner,Michael Koeppen,Tamam Backchoul,Nisar P. Malek,Rupert Handgretinger,Peter Rosenberger,Valbona Mirakaj +10 more
Reads0
Chats0
TLDR
The COVID-19 pandemic reached Germany in spring 2020 and no proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID19-induced ARDS as mentioned in this paper.Abstract:
Background:The COVID-19 pandemic reached Germany in spring 2020. No proven treatment for SARS-CoV-2 was available at that time, especially for severe COVID-19-induced ARDS. We determined whether th...read more
Citations
More filters
Journal ArticleDOI
Mesenchymal stem cell therapy on top of triple therapy with remdesivir, dexamethasone, and tocilizumab improves PaO2/FiO2 in severe COVID-19 pneumonia
Chih Hao Chen,Kuan-Cheng Chang,Yen-Nien Lin,Mao-Wang Ho,Meng-yu Cheng,Wen-Hsin Shih,Chia-Huei Chou,Po-Chang Lin,Chih-Yu Chi,Min Liu,Ni-Ke Tien,Mei-Yao Wu,Shih-Sheng Chang,Wu-Huei Hsu,W.C. Shyu,Der Yang Cho,Long Bin Jeng +16 more
TL;DR: Transplantation of hUC-MSCs as adjunctive therapy improves pulmonary oxygenation in patients with severe or critical COVID-19, characterized by the reduction in both hs-CRP and MDW.
Journal ArticleDOI
Mechanisms of Potential Therapeutic Utilization of Mesenchymal Stem Cells in COVID-19 Treatment
Lei X. Sun,Wenwen Tan,X.H Fan +2 more
TL;DR: In this article , Mesenchymal stem cells (MSCs) or MSC-derived extracellular vesicles (MSC-EVs) by far have become the most promising candidates in preclinical studies and clinical trials, and MSCrelated therapies have shown their potential to treat severe COVID-19.
Journal ArticleDOI
The Therapeutic Significance of Mesenchymal Stem Cells in COVID-19 Acute Pulmonary Respiratory Disease
TL;DR: The mesenchymal stem cell application can prevent the development of post-coronavirus syndrome through the mechanism of an inflammasome as discussed by the authors , however, there is no study that analyzes the effects of current treatments using mesenchmal stem cells in the post-CORONAVIRUS disease period, and that tests the use of mesenchyal stemcells when postcoron avirus syndrome develops.
Peer Review
Safety and ef fi cacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis
TL;DR: It is demonstrated that MSCs are highly likely to reduce mortality and are safe to use for patients with severe or critical COVID-19, regardless of whether 1-3 doses are applied.
Posted ContentDOI
The safety and efficacy of mesenchymal stem cells in the treatment of COVID-19-associated pneumonia: a systematic review and meta-analysis
TL;DR: In this paper, the safety and effectiveness of mesenchymal stem cells (MSCs) in the treatment of COVID-19-associated pneumonia patients were systematically reviewed and analyzed.
References
More filters
Journal ArticleDOI
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more
TL;DR: During the first 2 months of the current outbreak, Covid-19 spread rapidly throughout China and caused varying degrees of illness, and patients often presented without fever, and many did not have abnormal radiologic findings.
Journal ArticleDOI
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.
Roy G. Brower,Michael A. Matthay,Alan H. Morris,David A. Schoenfeld,B. Taylor Thompson,Arthur P. Wheeler +5 more
TL;DR: In patients with acute lung injury and the acute respiratory distress syndrome, mechanical ventilation with a lower tidal volume than is traditionally used results in decreased mortality and increases the number of days without ventilator use.
Journal ArticleDOI
Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Giacomo Grasselli,Giacomo Grasselli,Alberto Zangrillo,Alberto Zanella,Alberto Zanella,Massimo Antonelli,Massimo Antonelli,Luca Cabrini,Antonio Castelli,Danilo Cereda,Antonio Coluccello,Giuseppe Foti,Roberto Fumagalli,Giorgio Antonio Iotti,Nicola Latronico,Luca Lorini,Stefano Merler,Giuseppe Natalini,Alessandra Piatti,Marco Ranieri,Anna Mara Scandroglio,Enrico Storti,Maurizio Cecconi,Antonio Pesenti,Antonio Pesenti +24 more
TL;DR: Patients with coronavirus disease 2019 (COVID-19) requiring treatment in an intensive care unit (ICU) in the Lombardy region of Italy were characterized, including data on clinical management, respiratory failure, and patient mortality.
Journal ArticleDOI
The trinity of COVID-19: immunity, inflammation and intervention.
Matthew Zirui Tay,Chek Meng Poh,Laurent Rénia,Laurent Rénia,Paul A. MacAry,Lisa F. P. Ng,Lisa F. P. Ng,Lisa F. P. Ng +7 more
TL;DR: The interaction of SARS-CoV-2 with the immune system and the subsequent contribution of dysfunctional immune responses to disease progression is described and the implications of these approaches for potential therapeutic interventions that target viral infection and/or immunoregulation are highlighted.
Journal ArticleDOI
Prone Positioning in Severe Acute Respiratory Distress Syndrome
Claude Guérin,Jean Reignier,Jean-Christophe Richard,Pascal Beuret,Arnaud Gacouin,Thierry Boulain,Emmanuelle Mercier,Michel Badet,Alain Mercat,Olivier Baudin,Marc Clavel,Delphine Chatellier,Samir Jaber,Sylvène Rosselli,Jordi Mancebo,Michel Sirodot,Gilles Hilbert,Christian Bengler,Jack Richecoeur,Marc Gainnier,Frédérique Bayle,Gael Bourdin,Véronique Leray,Raphaële Girard,Loredana Baboi,Louis Ayzac +25 more
TL;DR: In patients with severe ARDS, early application of prolonged prone-positioning sessions significantly decreased 28-day and 90-day mortality.
Related Papers (5)
Transplantation of ACE2 - Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.
Zikuan Leng,Rongjia Zhu,Wei Hou,Yingmei Feng,Yanlei Yang,Qin Han,Guangliang Shan,Fanyan Meng,Dongshu Du,Shihua Wang,Junfen Fan,Wenjing Wang,Luchan Deng,Hongbo Shi,Hongjun Li,Zhongjie Hu,Fengchun Zhang,Jinming Gao,Hongjian Liu,Xiaoxia Li,Yangyang Zhao,Kan Yin,Xijing He,Zhengchao Gao,Yibin Wang,Bo Yang,Ronghua Jin,Ilia Stambler,Lee Wei Lim,Huanxing Su,Alexey Moskalev,Antonio Cano,Sasanka Chakrabarti,Kyung-Jin Min,Georgina M. Ellison-Hughes,Calogero Caruso,Kunlin Jin,Robert Chunhua Zhao +37 more
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
Giacomo Lanzoni,E. Linetsky,Diego Correa,Shari Messinger Cayetano,Roger A. Alvarez,Dimitrios Kouroupis,Ana M. Alvarez Gil,Raffaella Poggioli,Phillip Ruiz,Antonio Marttos,Khemraj Hirani,Crystal A. Bell,Halina Kusack,Lisa E. Rafkin,David A. Baidal,Andrew Pastewski,Kunal Gawri,Clarissa Leñero,Alejandro Mantero,Sarah W. Metalonis,Xiaojing Wang,Luis Roque,Burlett Masters,Norma S. Kenyon,Enrique Ginzburg,Xiumin Xu,Jianming Tan,Arnold I. Caplan,Marilyn K. Glassberg,Rodolfo Alejandro,Camillo Ricordi +30 more